State Pharmacy Board Enforcement Against GLP-1 Compounders: A Patient Guide

The regulatory threat facing your compounded GLP-1 provider may be coming from Raleigh or Montgomery or Olympia — not just from the FDA in Silver Spring. State pharmacy boards have authority to suspend or revoke compounding licences immediately, often moving faster than any federal enforcement process. State attorneys general have obtained court orders freezing operations within days of filing.

Most coverage of the compounding regulatory landscape focuses on FDA. This article covers the state level, where enforcement has been just as active and, in several cases, more immediate. For the federal enforcement picture, see FDA compounding cliff.

The dual-jurisdiction reality

Compounding pharmacies exist under two simultaneous regulatory regimes:

Federal (FDA): Governs whether the product being compounded is legally permissible under the FD&C Act — shortage status, 503A vs 503B pathway, marketing claims, Good Manufacturing Practice standards. FDA enforces through warning letters, injunctions, and seizures. Injunctions require filing in federal court, which takes time.

State (pharmacy boards): Governs whether the pharmacy has a valid licence to compound in that state. State boards set their own sterile compounding standards (often following USP 797 guidelines), inspect facilities, require staff credentials, and can discipline, suspend, or revoke licences. A pharmacy without an active state licence cannot legally dispense prescriptions in that state.

These two frameworks are independent. A pharmacy can have no FDA warning letter and still lose its state licence. A pharmacy can receive an FDA warning letter and continue operating with a valid state licence. Patients tracking their provider’s status should check both.

The Washington State action: Aequita and sterile compounding

The highest-profile state enforcement action in the GLP-1 space was Washington State’s March 2025 action against Aequita Pharmacy LLC — a primary compounding partner for Mochi Health.

The Washington Pharmacy Quality Assurance Commission (PQAC) issued a Limited Stop Service order, restricting Aequita’s operations following an investigation that found:

• Untrained and unqualified staff performing sterile compounding procedures
• Inadequate supervision of sterile compounding activities
• Failure to adhere to the sterile compounding procedures required to ensure product integrity

The sterile compounding violations are the most serious category of pharmacy board finding. Unlike marketing-claims violations, sterile compounding failures directly affect patient safety — contamination or incorrect compounding of an injectable drug creates direct risk. For definitions of the terms used in enforcement, see the compounding glossary.

Mochi Health transitioned affected patients to other compounding pharmacies. The Aequita entity is also named as a co-defendant in Eli Lilly’s federal lawsuit against Mochi Health. That lawsuit and the state board action are separate legal proceedings, but both emerged from Aequita’s compounding operations.

The Aequita case is a model for what state-board-specific risk looks like: a pharmacy can be operating for years without federal enforcement attention, then face a state action that disrupts supply for thousands of patients in weeks.

State attorney general actions: the consumer protection route

State attorneys general have a separate enforcement pathway that operates even faster than pharmacy board proceedings: consumer protection law. Multiple state AGs used this tool in 2025.

Alabama, November 2025: The Alabama AG obtained a temporary restraining order against Aurora IV & Wellness, a weight-loss and infusion clinic, after finding that the clinic was administering compounds labelled “not for human use” or “for research purposes only” to paying patients while marketing them as pharmaceutical-grade weight-loss injections. The TRO froze clinic assets and suspended operations. Research-grade peptides — sold for laboratory use and subject to no pharmaceutical manufacturing standards — in clinical use represent one of the most dangerous compounding situations patients can encounter.

Connecticut, May 2025: The Connecticut Department of Consumer Protection issued a statewide warning to all weight-loss clinics and medspas operating GLP-1 programs. The warning specifically targeted claims that compounded products were “generic Ozempic” or FDA-approved equivalents. Connecticut later settled with Triggered Brand — requiring the company to cease state operations and pay monetary penalties — for selling bootleg compounded products as branded pharmaceutical products.

Ohio, January 2026: The Ohio State Board of Pharmacy fined a Columbus-area compounding pharmacy $15,000 after finding it was preparing bulk quantities of semaglutide without patient-specific prescriptions — a fundamental violation of 503A personalised-compounding requirements. A Cleveland pharmacy faced separate disciplinary action for using bulk substances sourced from overseas non-FDA-registered suppliers.

The research-grade risk

The Alabama case highlights a category of risk that receives less attention in mainstream coverage: research-grade peptides sold directly to consumers or used in unlicensed clinical settings.

Research-grade semaglutide and tirzepatide are sold as laboratory reagents — labelled “not for human use” — through suppliers that do not operate under pharmaceutical manufacturing standards. There is no verified sterility, no accurate concentration testing, no lot-release testing. Dosing a high-concentration research-grade vial incorrectly is how the majority of the 455+ adverse events FDA received for compounded semaglutide occurred.

Patients tracking GLP-1 communities will recognise the references — the subreddits that provide sourcing guidance for research-grade peptides at $4/mg or less — as a pathway some patients have turned to when manufacturer-direct pricing is out of reach. The frustration is legitimate: $349/month NovoCare pricing is unaffordable for many patients. But the risk profile of research-grade, direct-to-consumer, unpharmacist-supervised peptides is categorically different from §503A-compounded products from a licensed pharmacy. For an overview of how compounded vs brand semaglutide compare in terms of manufacturing standards, see that guide.

State attorneys general and health departments are now specifically targeting this category. The Alabama TRO was not against a licensed pharmacy — it was against a clinic that had sourced research-grade materials for clinical injection.

How to check your pharmacy’s state licence

Every US state maintains a public pharmacy licence lookup. The steps:

1. Identify which pharmacy actually compounds your medication (call your telehealth provider if the packaging doesn’t disclose it)
2. Search “[state name] pharmacy board licence lookup” to find the board’s public database
3. Search for the pharmacy by name or licence number
4. Check: is the licence active? Are there any disciplinary actions, probationary conditions, restrictions, or suspensions on file?

State pharmacy board records are public. A clean, active licence with no disciplinary history is the baseline you want to see. A record showing prior complaints, consent agreements, or licence restrictions should prompt further investigation.

Our compounding tracker incorporates known state enforcement actions alongside FDA warning letters — check it for current provider status before your next refill.

State enforcement actions sourced from state government press releases and agency public records as of May 2026. This article is informational only. Provider regulatory status changes rapidly; see the compounding tracker for current status. Related: FDA Warning Letters Explained · Novo Nordisk Lawsuit Against Compounders · Switch From Compounded to Brand